London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Anyone got a view ? .. educated guess? ... BA sale ends today so thinking of hedging on Fri 28th June ... thoughts?
It was on a Thursday last year.
Try calling our Broker they may be able to help. GL!
You could ask the company...;)
Our last significant update in September 2023 included the following:
"Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral "shedders", a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024."
It is not unreasonable to deduce that, seven and a half months later, there ought to have been a further update on the progress of the preparatory work, and the likely trial launch dates by now? As was the case during Winter 2022-2023, when we were anticipating something similar, a trial announcement is looking less likely with each passing day.
Is it possible that there may be a plan B afoot, as some investors here have suggested? My patience with the vague statements, obfuscation, and sheer arrogance from the CEO and his BOD over more than two years has long ran out. I am seriously doubting their competence in taking our treatment forward. Those who maintain that there is still six weeks left in H1 2024 have a point. However, should it always be the case of a last minute update from Synairgen, with a long period of silence beforehand? Good companies are not usually led in such a shabby way, with total disregard for LTIs in particular!
Thanks Mani ... No joy with brokers , message left at SNG HQ but not expecting a reply. Last 2 years was a Thursday so brought forward my 'hedge' to 27th ... early start to the w'end then!
The_Paladin: Agree with everything said. Re plan B...at the last AGM, Simon Shaw stated that he got the message loud and clear that SNG had to improve on their investor communications. I found him to be quite straight forward and willing to engage.
The severe lack of such improvement does support the theory that somrthing is going on at a strategic level.
We have to hope either J&J or AZ came here for something beyond UNIVERSAL - and that something is SNG. Chances that Synairgen has enough money left to complete the P2s - which should have been well underway it not finished by now - diminishing by the day. Best case scenario from here is a deal similar to one struck with AZ back in 2015. Worst case is that Synairgen are poddling along at their own speed with no significant partners and are not close to starting.
“Worst case is that Synairgen are poddling along at their own speed with no significant partners and are not close to starting.”
My gut feeling is just this. Oh how I want to be wrong.
"Best case scenario from here is a deal similar to one struck with AZ back in 2015". I wouldn't be so quick to mark your cards down. There's a lot we don't know. Worth remembering AZ and JJ are not the only BPs in Pandemic Prep Town. Hopefully the recent CFO will have been looking at non-dilutive routes to elongating our cash runway. He should have been doing that since Day 1 .
I'm guessing 2023 final year results will basically say cash position around £11 million left in bank and this should be 'imminent' 😂 !!
8 months since last actual news......................which stated :
'In summary, Synairgen is continuing to work at pace, partnering with high quality researchers and collaborators, to ensure it has the right trial designs, equipped with the right diagnostic tools, to be able to identify trial participants potentially most likely to benefit from a broad-spectrum antiviral and SNG001. This work (including biomarker assessments), together with the substantial body of evidence gathered from clinical trials with SNG001 to date, will inform a robust clinical development programme for SNG001. It is the Company's goal to commence trials as soon as possible, subject to approval timelines, and within H1 2024.' and
'The Company's cash resources are sufficient to cover its plans to design and establish data from an observational study and two investigator-led/Synairgen-sponsored Phase 2 clinical trials, including manufacture of active and placebo for use in these trials. Regardless of the outcome of these activities, which are uncertain, the Company's available resources are sufficient to cover existing committed costs and the estimated costs of these activities until at least 30 September 2024, being a period of at least twelve months from the date of this report and, for this reason, the financial statements have been prepared on a going concern basis.'
Well Buzz....................over to you !!!!! Give us LTI's some real hope !!!!
Beautiful corporate speak Fruits " Hopefully the recent CFO will have been looking at non-dilutive routes to elongating our cash runway. " but unless the company has the cash to complete its P2s and P3s there can be no free elongating of the cash runway and no chance of a non-dilutory deal.
When AZ came calling in 2014 it was effectively prepared to take SNG off Synairgen's hands. Handing over $7.5m and the promise of up to $225 of developmental investment - but taking almost all of the profits from eventual sales. AstraZeneca promised to pay tiered royalties ranging from single-digit up to mid-teens on commercial sales.
So in exchange for the potentially huge costs of getting it onto pharmacy shelves - AZ was taking the lot.
You'll say that Synairgen is in a stronger position now with decent data in certain patient cohorts and some of the future de-risked - but the bottom line is still the same. It needs someone else to pick up the tab to get it to market. Most of us understand that the cost of this will be huge in terms of surrendered equity, however it happens.
I reckon Marsden will step down before AGM, he won’t want to face angry Shareholders. He’s rinsed them for a tidy win thus far!
Non-dilutive funding options exist, so in the absence of evidence to the contrary, they can't be ruled out;
BARDA funds companies that develop medical countermeasures that address public health and the consequences of pandemic flu and emerging diseases like SARS-CoV-2 and COVID-19.
There are also partnering opportunities; we know that the company have actively attended such sessions previously. Many partnering arrangements and collaborations are mutually beneficial.
Another funding source from BARDA, in collaboration with NIAID, is Project NextGen. This initiative coordinates with the government and private sectors to advance new vaccines and therapeutics through R&D, clinical trials, and then get FDA authorisation.
There's also public-private partnerships, government research and industry grant funding from numerous sources.
Non-dilutive funding can't be ruled out unless the company say it is.
Lol!
"Most of us understand that the cost of this will be huge in terms of surrendered equity, however it happens."
Most of us should understand that there's no such thing as a free lunch. As long as any hypothetical dealis *mutually beneficial* (i.e. for Us it results in an approved drug that will meet clinical need and thus generate income, increase valuation, give us our well earned ROI, etc), then we should consider that a fair exchange. Quid pro quo. NO small biotech goes it alone. Sooner or later they all need scaffolding to get a drug(s) to market. I remain optimistic and openminded. The fat lady will soon sing.
Glad you agree Fruits. Pehaps you'll now ask the mods to take down the nonsense post about non - dilutory routes forward.
They had the free lunch in the autumn of 2020 - when we supported a placement which they've dined well on ever since and spent mostly on the ill conceived and fated Sprinter trial ( who was it that reported that PM said " in hindsight they'd have changed the endpoints to the same as SG016 " ... )
Despite this, I too am still reasonably, and unaccountably optimistic - given the utter shi.tshow of the last almost 9 months of silence, that one day inhaled interferon will be on offer in my local HDU, but it won't have Synairgen's name on it. If they don't have enough money to complete the trials, this once majestic porker will head for the BP slaughterhouse where we'll probably be looking at ( once the BoD has arranged its own safe and well upholstered private jet exit ) a leg, 3lbs of streaky and a couple of chipolatas. Would that be "mutually beneficial " enough for you ?